Business Wire

CD-CAPITAL

30.11.2022 11:05:38 CET | Business Wire | Press release

Share
CD Capital’s Carmel Daniele Successfully Nominated in 2022’s Edition of “100 Global Inspirational Women in Mining” (WIM100)

CD Capital is thrilled to announce Carmel Daniele’s successful nomination in 2022’s edition of “100 Global Inspirational Women in Mining” (WIM100), a biennial publication that celebrates the “above & beyond” contributions of women to the mining industry, across all roles, seniority and jurisdictions.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221129005553/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Carmel Daniele nominated in 2022's WIM100 (Photo: Business Wire)

CD Capital is proud that Ms Daniele has received this recognition for her pioneering work within the mining private equity sector. Ms Daniele, CD Capital’s Founder and Chief Investment Officer commented,

“I feel both honoured and humbled to have been nominated for this prestigious award to stand alongside many other pioneering women in our field. By working together, we make a powerful force in creating positive change for the future and inspiring other women to join our sector that is key to the greening of our planet for generations to come”.

Ms Daniele is a leader in her field, having established CD Capital in 2006, being one of the first in London to set up a dedicated fund focused on private mining assets and winning a prestigious mining finance industry award in 2008. She has since launched two further natural resource funds and has raised c.$1bn in capital from leading institutional investors. CD Capital’s global portfolio invests in the development of projects that will supply critical minerals for the green transition, as well as the key ingredients used in fertilisers to ensure food security for the world. Projects are primarily in jurisdictions that can rely on their own abundance of green energy, such as Latin America, Canada, Australia and Europe.

Since establishing CD Capital, Ms Daniele has built a world-class investment technical team of industry insiders. Ms Daniele also actively sponsors women studying Geology at Imperial College through its internship and mentoring programme.

The 100 Global Inspirational Women in Mining 2022 publication includes more on WIM100 on page 3 and features Ms Daniele on page 47. In 2022, WIM 100 received 915 nominations for 491 women in mining from 61 countries.

These 100 inspirational women have been chosen using the following selection criteria:

1. She is a trailblazer: A WIM100 woman is a pioneer. She is an innovator. She makes positive and impactful changes so the industry can operate in a more sustainable, inclusive and safer way.

2. She advocates and empowers: A WIM100 woman offers proactive advocacy to those working in the mining industry and beyond. She empowers her colleagues to ensure everyone feels heard, welcomed and respected.

3. She perseveres in the face of adversity: A WIM100 woman is resilient and determined. She has the courage to speak up, challenge the status quo and break barriers.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221129005553/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye